DaVita Inc. (DVA) fair value analysis

S&P 500 · Updated 2026-09-07

DaVita Inc. is a healthcare company that provides dialysis services and related treatments for patients with chronic kidney disease and end-stage renal disease. The company operates dialysis centers and related care facilities across the United States and in several international markets.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, DVA is trading at a 10–25% discount to estimated fair value.

DVA currently ranks #41 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $183.99
Sector: Healthcare
12-month range: $111.19–$240.09

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: C
Leverage: Low
Margin trend: Stable
Revenue growth: Modest
RSI zone: Neutral
52-week position: The upper-middle quarter of its range
DCF cross-check: Undervalued

What our data shows for DVA

Our model validated 17 trailing price-to-earnings windows for DVA, built from quarterly earnings records.
Shares are trading in the middle of their 12-month price range of $111.19–$240.09.
The 14-day relative strength index sits at a neutral 50.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for DVA
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent DVA news

TickrTrends' derived news-sentiment signal for DVA is currently mixed, computed from recent coverage.

Are Wall Street Analysts Bullish on DaVita Stock? (finance.yahoo.com, 2026-08-11)
TickrTrends take: DaVita operates in the Healthcare sector where valuation metrics can significantly influence investor positioning relative to analyst sentiment. TickrTrends currently identifies DVA as undervalued, which means the stock may be trading below what fundamental analysis suggests its worth should be. Investors focused on valuation should monitor whether the bullish analyst views translate into upward price adjustment that could narrow or close the gap between current market price and intrinsic value estimates.
DaVita signals 2026 midpoint guidance of $2.2B adjusted operating income and $14.65 EPS while planning expanded HD rollout (NYSE:DVA) (seekingalpha.com, 2026-08-05)
TickrTrends take: DaVita's 2026 guidance points to material earnings growth from its current baseline, which provides a concrete benchmark against which to assess whether the Undervalued designation can be sustained as the company executes its expanded hemodialysis rollout. The adjusted operating income and EPS targets represent specific financial milestones that valuation models typically use to project long-term cash generation in the healthcare services sector. Investors focused on valuation metrics should monitor whether the company achieves these 2026 targets, as execution risk on the HD expansion could influence whether current pricing reflects appropriate compensation for that business development.

What people are saying

Follow the DVA conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for DVA in the Healthcare sector shifted this week as the RSI zone moved from oversold to neutral territory. The current valuation verdict remains Undervalued. This movement in the RSI indicator reflects a moderate change in the stock's momentum positioning within the week.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is DVA stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), DVA is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is DVA's TickrTrends verdict?

DVA's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does DVA compare to other Healthcare stocks?

DVA ranks #41 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is DVA overbought or oversold?

DVA's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

DVA vs ABT · DVA vs BTSG · DVA vs COLL · DVA vs EXEL · DVA vs INCY